Funding and scale ITN operates as a funded clinical research network under a government health institution (NIAID/NIH), with a relatively small team (11-50 employees) and revenue in the 1-10M range, indicating a lean operation that may rely on partnerships and grant-based funding for expansion.

Clinical research focus Strategic opportunity in immune tolerance therapies across asthma, autoimmune diseases, type 1 diabetes, and solid organ transplantation suggests potential for CRO services, data analytics, trial management, and mechanistic studies aligned with immune modulation.

Tech stack leverage ITN’s use of cloud and web technologies (AWS, Drupal, Webflow, Microsoft 365) along with security and delivery protocols (HSTS, HTTP/3) indicates openness to digital infrastructure improvements, data platform integration, and secure collaboration tools.

Partnership potential As a collaborative network funding and enabling trials, ITN likely seeks strategic partners for clinical trial execution, lab-based mechanistic studies, data sharing platforms, and translational research infrastructure.

Growth opportunities Moderate revenue with mission-driven expansion into additional immune tolerance programs, potential for scale through sponsored trials, technology-enabled study platforms, and expanding to related therapeutic areas through NIAD/NIH-aligned initiatives.